China CRO To Establish Global Clinical Trial Network
This article was originally published in PharmAsia News
A leading Chinese CRO, Tigermed Consulting, has set up international clinical trial networks separately with Russian firm Outsourcing Clinical Trials (OCT) and Korean LSK Global Pharma Services. The strategic cooperation will allow Tigermed to provide full services for pharmaceutical multinationals as well as China's new drug R&D institutions. Industry insiders observe that OCT and LSK attach importance to Tigermed's international client resources and innovative drug R&D capacity. The latter aims to be one of the top CROs in the Asia Pacific region in three years and plans to expand international business through strategic collaborations. (Click here for more - Chinese Language)
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.